Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

IMW 2019 | Myeloma XI: Gareth Morgan update

Gareth Morgan • 13 Sep 2019
IMW 2019
Multiple Myeloma Bortezomib Carfilzomib Cyclophosphamide Lenalidomide Thalidomide
Myeloma XI

Gareth Morgan, MD, PhD, FRCP, FRCPath, NYU Langone Orthopedic Center, New York, NY, gives an update on the MYELOMA XI plus study (NCT01554852) at the International Myeloma Workshop (IMW) 2019, held in Boston, MA.

More from Gareth Morgan

Circulating malignant plasma cell biology in HRMM: detecting PR cells at the single cell level 7:13
Circulating malignant plasma cell biology in HRMM: detecting PR cells at the single cell level
Gareth Morgan et al. • 23 Oct 2025
Considering frailty in myeloma treatment decisions: advice for clinicians 2:17
Considering frailty in myeloma treatment decisions: advice for clinicians
Gareth Morgan • 18 Sep 2025
The challenges of managing high-risk myeloma and the need to optimize outcomes 2:55
The challenges of managing high-risk myeloma and the need to optimize outcomes
Gareth Morgan • 18 Sep 2025
Improving the diagnosis of amyloidosis: advice that can be applied in practice 2:48
Improving the diagnosis of amyloidosis: advice that can be applied in practice
Gareth Morgan • 18 Sep 2025

Related Videos

The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial 10:22
The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial
Peter Voorhees • 19 Nov 2025
Promising approaches being explored in high-risk myeloma & trials to look out for 2:11
Promising approaches being explored in high-risk myeloma & trials to look out for
Sham Mailankody • 24 Oct 2025
The value of extensive profiling in single-arm trials for high-risk myeloma 2:39
The value of extensive profiling in single-arm trials for high-risk myeloma
Martin Kaiser • 24 Oct 2025
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy? 2:35
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy?
Sham Mailankody • 24 Oct 2025
The content of VJHemOnc is intended for healthcare professionals